ADVERTISEMENT

Piramal Pharma Q1 Results Review - Strong Orderbook, Cost Efficiencies Boosting A Turnaround: ICICI Securities

Steady new order inflow in CDMO business, commercialisation of pipeline projects may drive revenue/Ebitda/PAT CAGR of ~15%/26%/368% over FY24-26E, says the brokerage.

<div class="paragraphs"><p>(Source: Piramal Pharma website)</p></div>
(Source: Piramal Pharma website)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More